Cartesian Therapeutics (RNAC) Competitors $11.30 +0.53 (+4.92%) Closing price 04:00 PM EasternExtended Trading$11.01 -0.29 (-2.56%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAC vs. PAHC, ABCL, NTLA, AMPH, WVE, AUPH, ARDX, ELVN, VERV, and NAGEShould you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Intellia Therapeutics (NTLA), Amphastar Pharmaceuticals (AMPH), WAVE Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), Ardelyx (ARDX), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry. Cartesian Therapeutics vs. Its Competitors Phibro Animal Health AbCellera Biologics Intellia Therapeutics Amphastar Pharmaceuticals WAVE Life Sciences Aurinia Pharmaceuticals Ardelyx Enliven Therapeutics Verve Therapeutics Niagen Bioscience Phibro Animal Health (NASDAQ:PAHC) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation. Does the media prefer PAHC or RNAC? In the previous week, Phibro Animal Health had 12 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 12 mentions for Phibro Animal Health and 0 mentions for Cartesian Therapeutics. Phibro Animal Health's average media sentiment score of 0.33 beat Cartesian Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Overall Sentiment Phibro Animal Health Neutral Cartesian Therapeutics Neutral Which has preferable earnings & valuation, PAHC or RNAC? Phibro Animal Health has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhibro Animal Health$1.02B1.20$2.42M$0.7838.62Cartesian Therapeutics$38.91M7.54-$77.42M-$52.83-0.21 Which has more risk and volatility, PAHC or RNAC? Phibro Animal Health has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Do institutionals & insiders believe in PAHC or RNAC? 99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is PAHC or RNAC more profitable? Phibro Animal Health has a net margin of 2.68% compared to Cartesian Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 30.51% beat Cartesian Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Phibro Animal Health2.68% 30.51% 6.89% Cartesian Therapeutics N/A N/A -7.01% Do analysts recommend PAHC or RNAC? Phibro Animal Health presently has a consensus target price of $24.40, indicating a potential downside of 18.99%. Cartesian Therapeutics has a consensus target price of $40.67, indicating a potential upside of 259.88%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cartesian Therapeutics is more favorable than Phibro Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phibro Animal Health 2 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.83Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryPhibro Animal Health beats Cartesian Therapeutics on 11 of the 16 factors compared between the two stocks. Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAC vs. The Competition Export to ExcelMetricCartesian TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$279.53M$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio-0.2120.8027.0020.10Price / Sales7.54286.98435.75120.29Price / CashN/A41.1936.8257.86Price / Book-41.857.487.985.56Net Income-$77.42M-$55.04M$3.16B$248.40M7 Day Performance3.76%5.44%3.69%6.04%1 Month Performance2.45%2.38%2.91%7.69%1 Year Performance-32.82%5.53%34.30%20.97% Cartesian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNACCartesian Therapeutics1.4099 of 5 stars$11.30+4.9%$40.67+259.9%-36.5%$279.53M$38.91M-0.2164PAHCPhibro Animal Health3.673 of 5 stars$29.90+6.8%$24.40-18.4%+77.4%$1.13B$1.02B38.331,940News CoverageAnalyst UpgradeHigh Trading VolumeABCLAbCellera Biologics2.5457 of 5 stars$4.03+6.1%$7.50+86.1%+49.8%$1.13B$28.83M-7.20500News CoverageAnalyst ForecastHigh Trading VolumeNTLAIntellia Therapeutics4.6881 of 5 stars$10.25-4.6%$33.37+225.5%-55.0%$1.11B$57.88M-1.96600AMPHAmphastar Pharmaceuticals4.4152 of 5 stars$22.86-1.5%$32.33+41.4%-39.4%$1.09B$731.97M8.282,028WVEWAVE Life Sciences4.4256 of 5 stars$7.06+1.6%$20.50+190.4%+29.1%$1.08B$108.30M-8.40240News CoverageAUPHAurinia Pharmaceuticals2.5572 of 5 stars$7.47-1.6%$11.50+53.9%+33.2%$1.03B$235.13M26.68300ARDXArdelyx4.4338 of 5 stars$4.35+1.9%$10.89+150.3%-17.8%$1.02B$333.61M-19.7790ELVNEnliven Therapeutics2.6688 of 5 stars$19.59-5.5%$41.20+110.3%-12.6%$1.02BN/A-10.2050VERVVerve Therapeutics3.4559 of 5 stars$11.16-1.1%$14.57+30.6%+112.6%$1.01B$59.61M-5.29110NAGENiagen Bioscience1.2984 of 5 stars$12.44-2.1%$19.50+56.8%N/A$1.00B$99.60M73.18120 Related Companies and Tools Related Companies PAHC Competitors ABCL Competitors NTLA Competitors AMPH Competitors WVE Competitors AUPH Competitors ARDX Competitors ELVN Competitors VERV Competitors NAGE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAC) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
